JP2009501746A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009501746A5 JP2009501746A5 JP2008521876A JP2008521876A JP2009501746A5 JP 2009501746 A5 JP2009501746 A5 JP 2009501746A5 JP 2008521876 A JP2008521876 A JP 2008521876A JP 2008521876 A JP2008521876 A JP 2008521876A JP 2009501746 A5 JP2009501746 A5 JP 2009501746A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- ethyl
- purin
- trans
- imidazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 2-Ethyl-2H-tetrazol-5-yl Chemical group 0.000 claims 16
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 7
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000004435 hydrogen atoms Chemical class [H]* 0.000 claims 2
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims 1
- 125000002877 alkyl aryl group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 200000000018 inflammatory disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
Claims (9)
R1は、メチルまたはエチルを表し;
R2は、下記のリスト:
R3は、下記のリスト:
ここで、R4は、下記のリスト:
R5は、水素、C1-4アルキル、C1-4アルキルアリール、C1-4アルキルヘテロアリールまたはC1-4ヒドロキシアルキルを表し;
R6およびR7は独立して、水素、メチルまたはフェニルを表す]
の化合物、ならびにその塩および溶媒和物。 Formula (I):
R 1 represents methyl or ethyl;
R 2 has the following list:
R 3 lists below:
Where R 4 is the list below:
R 5 represents hydrogen, C 1-4 alkyl, C 1-4 alkylaryl, C 1-4 alkylheteroaryl or C 1-4 hydroxyalkyl;
R 6 and R 7 independently represent hydrogen, methyl or phenyl]
And their salts and solvates.
(2R,3S,4R,5R)-2-(2-エチル-2H-テトラゾール-5-イル)-5-[2-{[2-(1-メチル-1H-イミダゾール-4-イル)エチル]アミノ}-6-({trans-4-[(2-{[2-(1-メチル-1H-イミダゾール-4-イル)エチル]アミノ}-1H-プリン-6-イル)アミノ]シクロヘキシル}アミノ)-9H-プリン-9-イル]テトラヒドロ-3,4-フランジオール;
(2R,3S,4R,5R)-2-(2-エチル-2H-テトラゾール-5-イル)-5-[2-{[2-(5-メチル-1H-イミダゾール-4-イル)エチル]アミノ}-6-({trans-4-[(2-{[2-(5-メチル-1H-イミダゾール-4-イル)エチル]アミノ}-1H-プリン-6-イル)アミノ]シクロヘキシル}アミノ)-9H-プリン-9-イル]テトラヒドロ-3,4-フランジオール;
(2R,3S,4R,5R)-2-(2-エチル-2H-テトラゾール-5-イル)-5-[2-{[4-(1-ピロリジニル)ブチル]アミノ}-6-({trans-4-[(2-{[4-(1-ピロリジニル)ブチル]アミノ}-1H-プリン-6-イル)アミノ]シクロヘキシル}アミノ)-9H-プリン-9-イル]テトラヒドロ-3,4-フランジオール;
(2R,3R,4S,5R)-2-(2-[(trans-4-アミノシクロヘキシル)アミノ]-6-{[trans-4-({2-[(trans-4-アミノシクロヘキシル)アミノ]-9H-プリン-6-イル}アミノ)シクロヘキシル]アミノ}-9H-プリン-9-イル)-5-(2-エチル-2H-テトラゾール-5-イル)テトラヒドロ-3,4-フランジオール;
(2R,3S,4R,5R)-2-(2-エチル-2H-テトラゾール-5-イル)-5-[2-{[2-(1H-イミダゾール-4-イル)エチル]アミノ}-6-({trans-4-[(2-{[2-(1H-イミダゾール-4-イル)エチル]アミノ}-4-ピリミジニル)アミノ]シクロヘキシル}アミノ)-9H-プリン-9-イル]テトラヒドロ-3,4-フランジオール;
(2R,3S,4R,5R)-2-(2-エチル-2H-テトラゾール-5-イル)-5-[2-{[2-(1-メチル-1H-イミダゾール-4-イル)エチル]アミノ}-6-({trans-4-[(2-{[2-(1-メチル-1H-イミダゾール-4-イル)エチル]アミノ}-4-ピリミジニル)アミノ]シクロヘキシル}アミノ)-9H-プリン-9-イル]テトラヒドロ-3,4-フランジオール;
(2R,3S,4R,5R)-2-(2-エチル-2H-テトラゾール-5-イル)-5-[2-{[2-(5-メチル-1H-イミダゾール-4-イル)エチル]アミノ}-6-({trans-4-[(2-{[2-(5-メチル-1H-イミダゾール-4-イル)エチル]アミノ}-4-ピリミジニル)アミノ]シクロヘキシル}アミノ)-9H-プリン-9-イル]テトラヒドロ-3,4-フランジオール;
(2R,3S,4R,5R)-2-(2-エチル-2H-テトラゾール-5-イル)-5-[2-{[4-(1-ピロリジニル)ブチル]アミノ}-6-({trans-4-[(2-{[4-(1-ピロリジニル)ブチル]アミノ}-4-ピリミジニル)アミノ]シクロヘキシル}アミノ)-9H-プリン-9-イル]テトラヒドロ-3,4-フランジオール;
(2R,3R,4S,5R)-2-(2-[(trans-4-アミノシクロヘキシル)アミノ]-6-{[trans-4-({2-[(trans-4-アミノシクロヘキシル)アミノ]-4-ピリミジニル}アミノ)シクロヘキシル]アミノ}-9H-プリン-9-イル)-5-(2-エチル-2H-テトラゾール-5-イル)テトラヒドロ-3,4-フランジオール;
である式(I)の化合物、またはそれらのいずれか1つの塩もしくは溶媒和物。 (2R, 3S, 4R, 5R) -2- (2-Ethyl-2H-tetrazol-5-yl) -5- [2-{[2- (1H-imidazol-4-yl) ethyl] amino} -6 -({trans-4-[(2-{[2- (1H-imidazol-4-yl) ethyl] amino} -1H-purin-6-yl) amino] cyclohexyl} amino) -9H-purine-9- Yl] tetrahydro-3,4-furandol;
(2R, 3S, 4R, 5R) -2- (2-Ethyl-2H-tetrazol-5-yl) -5- [2-{[2- (1-methyl-1H-imidazol-4-yl) ethyl] Amino} -6-({trans-4-[(2-{[2- (1-methyl-1H-imidazol-4-yl) ethyl] amino} -1H-purin-6-yl) amino] cyclohexyl} amino ) -9H-purin-9-yl] tetrahydro-3,4-furandol;
(2R, 3S, 4R, 5R) -2- (2-Ethyl-2H-tetrazol-5-yl) -5- [2-{[2- (5-methyl-1H-imidazol-4-yl) ethyl] Amino} -6-({trans-4-[(2-{[2- (5-methyl-1H-imidazol-4-yl) ethyl] amino} -1H-purin-6-yl) amino] cyclohexyl} amino ) -9H-purin-9-yl] tetrahydro-3,4-furandol;
(2R, 3S, 4R, 5R) -2- (2-Ethyl-2H-tetrazol-5-yl) -5- [2-{[4- (1-pyrrolidinyl) butyl] amino} -6-({trans -4-[(2-{[4- (1-pyrrolidinyl) butyl] amino} -1H-purin-6-yl) amino] cyclohexyl} amino) -9H-purin-9-yl] tetrahydro-3,4- Flange all;
(2R, 3R, 4S, 5R) -2- (2-[(trans-4-aminocyclohexyl) amino] -6-{[trans-4-({2-[(trans-4-aminocyclohexyl) amino] -9H-purin-6-yl} amino) cyclohexyl] amino} -9H-purin-9-yl) -5- (2-ethyl-2H-tetrazol-5-yl) tetrahydro-3,4-furandol;
(2R, 3S, 4R, 5R) -2- (2-Ethyl-2H-tetrazol-5-yl) -5- [2-{[2- (1H-imidazol-4-yl) ethyl] amino} -6 -({trans-4-[(2-{[2- (1H-imidazol-4-yl) ethyl] amino} -4-pyrimidinyl) amino] cyclohexyl} amino) -9H-purin-9-yl] tetrahydro- 3,4-flangeol;
(2R, 3S, 4R, 5R) -2- (2-Ethyl-2H-tetrazol-5-yl) -5- [2-{[2- (1-methyl-1H-imidazol-4-yl) ethyl] Amino} -6-({trans-4-[(2-{[2- (1-methyl-1H-imidazol-4-yl) ethyl] amino} -4-pyrimidinyl) amino] cyclohexyl} amino) -9H- Purin-9-yl] tetrahydro-3,4-furandol;
(2R, 3S, 4R, 5R) -2- (2-Ethyl-2H-tetrazol-5-yl) -5- [2-{[2- (5-methyl-1H-imidazol-4-yl) ethyl] Amino} -6-({trans-4-[(2-{[2- (5-methyl-1H-imidazol-4-yl) ethyl] amino} -4-pyrimidinyl) amino] cyclohexyl} amino) -9H- Purin-9-yl] tetrahydro-3,4-furandol;
(2R, 3S, 4R, 5R) -2- (2-Ethyl-2H-tetrazol-5-yl) -5- [2-{[4- (1-pyrrolidinyl) butyl] amino} -6-({trans -4-[(2-{[4- (1-pyrrolidinyl) butyl] amino} -4-pyrimidinyl) amino] cyclohexyl} amino) -9H-purin-9-yl] tetrahydro-3,4-furandol;
(2R, 3R, 4S, 5R) -2- (2-[(trans-4-aminocyclohexyl) amino] -6-{[trans-4-({2-[(trans-4-aminocyclohexyl) amino] -4-pyrimidinyl} amino) cyclohexyl] amino} -9H-purin-9-yl) -5- (2-ethyl-2H-tetrazol-5-yl) tetrahydro-3,4-furandol;
Or a salt or solvate of any one of them.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0514809.3A GB0514809D0 (en) | 2005-07-19 | 2005-07-19 | Compounds |
GB0514809.3 | 2005-07-19 | ||
PCT/EP2006/007078 WO2007009757A1 (en) | 2005-07-19 | 2006-07-17 | Purine derivatives as agonists of the adenosine a2a receptor |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2009501746A JP2009501746A (en) | 2009-01-22 |
JP2009501746A5 true JP2009501746A5 (en) | 2009-08-27 |
JP5010599B2 JP5010599B2 (en) | 2012-08-29 |
Family
ID=34897468
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008521876A Expired - Fee Related JP5010599B2 (en) | 2005-07-19 | 2006-07-17 | Purine derivatives that are agonists of adenosine A2A receptors |
Country Status (9)
Country | Link |
---|---|
US (1) | US7985740B2 (en) |
EP (1) | EP1904512B1 (en) |
JP (1) | JP5010599B2 (en) |
AR (1) | AR054559A1 (en) |
ES (1) | ES2387404T3 (en) |
GB (1) | GB0514809D0 (en) |
PE (1) | PE20070179A1 (en) |
TW (1) | TW200740814A (en) |
WO (1) | WO2007009757A1 (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1434782A2 (en) * | 2001-10-01 | 2004-07-07 | University of Virginia Patent Foundation | 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof |
JP5046930B2 (en) * | 2004-08-02 | 2012-10-10 | ユニバーシティ オブ バージニア パテント ファウンデーション | 2-propynyladenosine analogs with modified 5'-ribose groups having A2A agonist activity |
GT200500281A (en) * | 2004-10-22 | 2006-04-24 | Novartis Ag | ORGANIC COMPOUNDS. |
GB0500785D0 (en) * | 2005-01-14 | 2005-02-23 | Novartis Ag | Organic compounds |
GB0523778D0 (en) * | 2005-11-23 | 2006-01-04 | Glaxo Group Ltd | Novel method |
WO2007120972A2 (en) * | 2006-02-10 | 2007-10-25 | University Of Virginia Patent Foundation | Method to treat sickle cell disease |
PL2013211T3 (en) * | 2006-04-21 | 2012-08-31 | Novartis Ag | Purine derivatives for use as adenosin a2a receptor agonists |
GB0607950D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
US8188063B2 (en) * | 2006-06-19 | 2012-05-29 | University Of Virginia Patent Foundation | Use of adenosine A2A modulators to treat spinal cord injury |
WO2008000743A2 (en) * | 2006-06-27 | 2008-01-03 | Biovitrum Ab (Publ) | Novel 2',3'-methylidene acetyl adenosine prodrugs for use as prodrugs for adenosine receptor agonists |
EP1889846A1 (en) * | 2006-07-13 | 2008-02-20 | Novartis AG | Purine derivatives as A2a agonists |
EP1903044A1 (en) * | 2006-09-14 | 2008-03-26 | Novartis AG | Adenosine Derivatives as A2A Receptor Agonists |
JP2010508835A (en) * | 2006-11-10 | 2010-03-25 | ノバルティス アーゲー | Cyclopentenediol monoacetate derivative |
US8058259B2 (en) | 2007-12-20 | 2011-11-15 | University Of Virginia Patent Foundation | Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists |
US8916570B2 (en) | 2008-03-31 | 2014-12-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A3 adenosine receptor agonists and antagonists |
CA2720037C (en) | 2008-03-31 | 2016-08-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Purine derivatives as a3 adenosine receptor-selective agonists |
US9181253B2 (en) | 2008-08-01 | 2015-11-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adenosine receptor agonists, partial agonists, and antagonists |
US8796291B2 (en) | 2008-08-01 | 2014-08-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A3 adenosine receptor antagonists and partial agonists |
Family Cites Families (215)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE768925A (en) | 1970-06-30 | 1971-11-03 | Takeda Chemical Industries Ltd | ADENOSINE DERIVATIVES AND METHOD OF PREPARATION |
US4224438A (en) * | 1970-07-14 | 1980-09-23 | Boehringer Mannheim Gmbh | Adenosine-5'-carboxylic acid amides |
DE2034785A1 (en) | 1970-07-14 | 1972-01-20 | Boehnnger Mannheim GmbH, 6800 Mann heim Waldhof | Adenosine 5 carboxylic acid derivatives |
CA1019727A (en) | 1971-03-18 | 1977-10-25 | Abbott Laboratories | Adenosine-5'-carboxylic acid amides |
BE789773A (en) | 1971-10-08 | 1973-04-06 | Schering Ag | ADENOSINES N6 -SUBSTITUTED AND THEIR PROCESS FOR |
US3864483A (en) | 1972-03-22 | 1975-02-04 | Abbott Lab | Adenosine-5{40 -carboxylic acid amides |
CA1082695A (en) | 1972-04-10 | 1980-07-29 | Francis E. Fischer | Process for preparing adenosine-5'-carboxamides |
US3966917A (en) | 1974-07-30 | 1976-06-29 | Abbott Laboratories | Platelet aggregation inhibitors |
DE2621470A1 (en) | 1976-05-14 | 1977-12-01 | Pharma Waldhof Gmbh & Co | Nucleoside carboxylic acid nitriles and derivs. - prepd. from a (5')-(O)-tosylated or halogenated nucleoside and a metal cyanide or alpha:alkali acetic acid |
US4167565A (en) | 1976-11-08 | 1979-09-11 | Abbott Laboratories | Adenosine-5'-carboxamides and method of use |
AU8379182A (en) | 1981-06-04 | 1982-12-09 | Procter & Gamble Company, The | Composition of salicylates and purine derivatives |
CA1239397A (en) | 1983-08-01 | 1988-07-19 | James A. Bristol | N.sup.6-substituted adenosines |
DE3406533A1 (en) | 1984-02-23 | 1985-08-29 | Boehringer Mannheim Gmbh, 6800 Mannheim | USE OF ADENOSINE DERIVATIVES AS ANTIALLERGICA AND MEDICINAL PRODUCTS CONTAINING THEM |
JPH0655756B2 (en) | 1984-04-18 | 1994-07-27 | ネルソン・リサ−チ・アンド・デベロツプメント・カンパニ− | N-6-substituted adenosine derivatives as cardiovascular vasodilators |
US5310731A (en) | 1984-06-28 | 1994-05-10 | Whitby Research, Inc. | N-6 substituted-5'-(N-substitutedcarboxamido)adenosines as cardiac vasodilators and antihypertensive agents |
AU575438B2 (en) | 1984-10-26 | 1988-07-28 | Warner-Lambert Company | N6 - substituted deoxyribose analogues of adenosines |
CA1254888A (en) | 1984-10-26 | 1989-05-30 | Bharat Trivedi | N.sup.6-bicycloadenosines |
US4663313A (en) | 1984-10-26 | 1987-05-05 | Warner-Lambert Company | N6 -tricyclic adenosines for treating hypertension |
US4738954A (en) | 1985-11-06 | 1988-04-19 | Warner-Lambert Company | Novel N6 -substituted-5'-oxidized adenosine analogs |
US4755594A (en) | 1986-01-31 | 1988-07-05 | Warner-Lambert Company | N6 -substituted adenosines |
US5106837A (en) | 1988-03-16 | 1992-04-21 | The Scripps Research Institute | Adenosine derivatives with therapeutic activity |
US4757747A (en) * | 1986-04-08 | 1988-07-19 | Vickers, Incorporated | Power transmission |
JPH0696534B2 (en) | 1986-04-25 | 1994-11-30 | ヘキストジヤパン株式会社 | Anti-dementia agent |
US4767747A (en) | 1986-08-28 | 1988-08-30 | Warner-Lambert Company | Method for treating congestive heart failure with N6 -acenaphthyl adenosine |
WO1988003147A1 (en) | 1986-10-31 | 1988-05-05 | Warner-Lambert Company | Selected n6-substituted adenosines having selective a2 binding activity |
WO1988003148A2 (en) | 1986-10-31 | 1988-05-05 | Warner-Lambert Company | Heteroaromatic derivatives of adenoside |
NL8702926A (en) | 1986-12-15 | 1988-07-01 | Sandoz Ag | NEW FURANURONIC ACID DERIVATIVES AND METHODS FOR PREPARING AND USING THESE DERIVATIVES. |
US4968697A (en) | 1987-02-04 | 1990-11-06 | Ciba-Geigy Corporation | 2-substituted adenosine 5'-carboxamides as antihypertensive agents |
PT86660B (en) | 1987-02-04 | 1992-02-28 | Ciba Geigy Ag | PROCESS FOR THE PREPARATION OF ADENOSIN-5'-CARBOXAMIDE DERIVATIVES |
US4962194A (en) | 1987-04-02 | 1990-10-09 | Warner-Lambert Company | Method of preparing 51,N6-disubstituted adenosines from inosines |
LU87181A1 (en) | 1987-04-06 | 1988-11-17 | Sandoz Sa | NOVEL DERIVATIVES OF FURANNURONIC ACID, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS |
US5219840A (en) | 1987-04-06 | 1993-06-15 | Sandoz Ltd. | Antihypertensive 9-(2,N6 -disubstituted adenyl) ribofuranuronic acid derivatives |
JPH0725785B2 (en) | 1989-01-11 | 1995-03-22 | 日本臓器製薬株式会社 | Adenosine derivative and pharmaceutical composition containing the compound as an active ingredient |
DE3924424A1 (en) * | 1989-07-24 | 1991-01-31 | Boehringer Mannheim Gmbh | NUCLEOSIDE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS A MEDICINAL PRODUCT AND THEIR USE IN THE SEQUENCING OF NUCLEIC ACID |
US5646128A (en) | 1989-09-15 | 1997-07-08 | Gensia, Inc. | Methods for treating adenosine kinase related conditions |
US5055569A (en) | 1989-10-19 | 1991-10-08 | G. D. Searle & Co. | N-(6)-substituted adenosine compounds |
PT95628A (en) | 1989-10-19 | 1991-09-30 | Searle & Co | METHOD OF TREATMENT OF GASTROINTESTINAL MOBILITY DISTURBACTIONS WITH ADENOSIN COMPOUND |
WO1991010671A1 (en) | 1990-01-11 | 1991-07-25 | Isis Pharmaceuticals, Inc. | Compositions and methods for detecting and modulating rna activity and gene expression |
US5459255A (en) * | 1990-01-11 | 1995-10-17 | Isis Pharmaceuticals, Inc. | N-2 substituted purines |
US5140015A (en) | 1990-02-20 | 1992-08-18 | Whitby Research, Inc. | 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents |
GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
US5280015A (en) | 1990-09-05 | 1994-01-18 | The United States Of America As Represented By The Department Of Health And Human Services | 2-substituted adenosines and 2-substituted adenosine 5'-carboxamides |
CA2092305C (en) | 1990-09-25 | 2003-02-11 | Alfred P. Spada | Compounds having antihypertensive and anti-ischemic properties |
CA2100863A1 (en) | 1991-01-23 | 1992-07-24 | David A. Bullough | Adenosine kinase inhibitors |
GB9127376D0 (en) | 1991-12-24 | 1992-02-19 | Wellcome Found | Amidino derivatives |
FR2685918B1 (en) | 1992-01-08 | 1995-06-23 | Union Pharma Scient Appl | NOVEL ADENOSINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
FR2687678B1 (en) | 1992-01-31 | 1995-03-31 | Union Pharma Scient Appl | NOVEL ADENOSINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
WO1993019749A1 (en) | 1992-04-02 | 1993-10-14 | Smithkline Beecham Corporation | Compounds useful for treating allergic and inflammatory diseases |
US5424297A (en) | 1992-04-27 | 1995-06-13 | University Of Virginia Alumni Patents Foundation | Adenosine dextran conjugates |
WO1994002497A1 (en) | 1992-07-15 | 1994-02-03 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Sulfo-derivatives of adenosine |
GB9301000D0 (en) | 1993-01-20 | 1993-03-10 | Glaxo Group Ltd | Chemical compounds |
WO1994018215A1 (en) | 1993-02-03 | 1994-08-18 | Gensia, Inc. | Adenosine kinase inhibitors comprising lyxofuranosyl derivatives |
IL108523A0 (en) | 1993-02-03 | 1994-05-30 | Gensia Inc | Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain |
US5773423A (en) | 1993-07-13 | 1998-06-30 | The United States Of America As Represented By The Department Of Health And Human Services | A3 adenosine receptor agonists |
US5446046A (en) | 1993-10-28 | 1995-08-29 | University Of Florida Research Foundation | A1 adenosine receptor agonists and antagonists as diuretics |
WO1995018817A1 (en) | 1994-01-07 | 1995-07-13 | Laboratoires Upsa | Novel adenosine derivatives, preparation methods therefor, and pharmaceutical compositions containing same |
AU692892B2 (en) | 1994-06-15 | 1998-06-18 | Wellcome Foundation Limited, The | Enzyme inhibitors |
GB9414208D0 (en) | 1994-07-14 | 1994-08-31 | Glaxo Group Ltd | Compounds |
GB9414193D0 (en) | 1994-07-14 | 1994-08-31 | Glaxo Group Ltd | Compounds |
JPH11505702A (en) | 1995-05-18 | 1999-05-25 | コールター インターナショナル コーポレイション | Assay reagents and methods of making and using the assay reagents |
US6403599B1 (en) | 1995-11-08 | 2002-06-11 | Pfizer Inc | Corticotropin releasing factor antagonists |
US5789589A (en) | 1996-04-22 | 1998-08-04 | Drug Innovation & Design, Inc. | Guanine analog phosphates |
WO1998001459A1 (en) | 1996-07-05 | 1998-01-15 | Novo Nordisk A/S | Novel n-alkoxyadenine derivatives acting as cytokine inhibitors |
UA51716C2 (en) | 1996-07-08 | 2002-12-16 | Авентіс Фармасьютікалз Продактс Інк. | combinations possessing hypotensive, cardioprotective, anti-ishemic, and antilipolytic agents, a pharmaceutical composition and METHOD OF TREATMENT |
WO1998016539A1 (en) | 1996-10-14 | 1998-04-23 | Novo Nordisk A/S | Novel therapeutically active adenosine derivatives |
FR2757518B1 (en) | 1996-12-23 | 1999-06-11 | Hoechst Marion Roussel Inc | NOVEL ERYTHROMYCIN DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR APPLICATION AS MEDICAMENTS |
TW528755B (en) * | 1996-12-24 | 2003-04-21 | Glaxo Group Ltd | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives |
WO1998030900A2 (en) | 1997-01-06 | 1998-07-16 | Klaus Trier Aps | Screening method for compounds active in treating myopia and hypermetropia |
MY117948A (en) | 1997-01-13 | 2004-08-30 | Glaxo Group Ltd | Nitride oxide synthase inhibitors. |
DE19723722A1 (en) | 1997-05-30 | 1998-12-10 | Schering Ag | Nonsteroidal progestogens |
WO1999016766A1 (en) | 1997-10-01 | 1999-04-08 | Kyowa Hakko Kogyo Co., Ltd. | Benzodioxole derivatives |
YU44900A (en) | 1998-01-31 | 2003-01-31 | Glaxo Group Limited | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives |
US6506766B1 (en) | 1998-02-13 | 2003-01-14 | Abbott Laboratories | Glucocortiocoid-selective antinflammatory agents |
PE20000270A1 (en) | 1998-02-14 | 2000-05-20 | Glaxo Group Ltd | DERIVATIVES OF 2- (PURIN-9-IL) -TETRAHIDROFURAN-3,4-DIOL |
CA2323771A1 (en) | 1998-03-14 | 1999-09-23 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Phthalazinone pde iii/iv inhibitors |
GB9811599D0 (en) | 1998-05-30 | 1998-07-29 | Glaxo Group Ltd | Nitric oxide synthase inhibitors |
GB9813540D0 (en) | 1998-06-23 | 1998-08-19 | Glaxo Group Ltd | Chemical compounds |
GB9813535D0 (en) * | 1998-06-23 | 1998-08-19 | Glaxo Group Ltd | Chemical compounds |
ID29609A (en) * | 1998-06-23 | 2001-09-06 | Glaxo Group Ltd | DURUNAN 2- (PURIN-9-IL) -TETRAHIDROFURAN-3,4-DIOL |
GB9813565D0 (en) | 1998-06-23 | 1998-08-19 | Glaxo Group Ltd | Chemical compounds |
US7427606B2 (en) * | 1999-02-01 | 2008-09-23 | University Of Virginia Patent Foundation | Method to reduce inflammatory response in transplanted tissue |
US7378400B2 (en) * | 1999-02-01 | 2008-05-27 | University Of Virginia Patent Foundation | Method to reduce an inflammatory response from arthritis |
US6232297B1 (en) * | 1999-02-01 | 2001-05-15 | University Of Virginia Patent Foundation | Methods and compositions for treating inflammatory response |
MY121142A (en) | 1999-02-23 | 2005-12-30 | Smithkline Beecham Corp | Controlled release formulation for treating copd |
CA2371273A1 (en) | 1999-05-04 | 2000-11-09 | Andrew Fensome | Tetracyclic progesterone receptor modulator compounds and methods |
WO2001002400A1 (en) | 1999-07-02 | 2001-01-11 | Eisai Co., Ltd. | Fused imidazole compounds and remedies for diabetes mellitus |
ES2165768B1 (en) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | NEW DERIVATIVES OF QUINUCLIDINE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM. |
US6263209B1 (en) | 1999-07-28 | 2001-07-17 | Motorola, Inc. | Method and apparatus in a wireless communication system for creating a learning function |
CO5180649A1 (en) | 1999-09-01 | 2002-07-30 | Abbott Lab | ANTAGONISTS OF GLUCOCORTICOID RECEPTORS FOR THE TREATMENT OF DIABETES FOR THE TREATMENT OF DIABETES |
US6803457B1 (en) | 1999-09-30 | 2004-10-12 | Pfizer, Inc. | Compounds for the treatment of ischemia |
OA11558A (en) | 1999-12-08 | 2004-06-03 | Advanced Medicine Inc | Beta 2-adrenergic receptor agonists. |
ES2223772T3 (en) | 2000-01-31 | 2005-03-01 | Pfizer Products Inc. | PYRIMIDINCARBOXAMIDS USED AS INHIBITORS OF THE ISOZIMAS PDE4. |
EE200200425A (en) | 2000-01-31 | 2003-10-15 | Pfizer Products Inc. | Benzocondensed heterocyclyl derivatives of nicotinamide useful as inhibitors of selective PDE4 isozymes |
US7585847B2 (en) | 2000-02-03 | 2009-09-08 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for the treatment of asthma and allergy |
US6710086B1 (en) | 2000-02-25 | 2004-03-23 | Medinox, Inc. | Protected forms of pharmacologically active agents and uses therefor |
US6753322B2 (en) | 2000-06-06 | 2004-06-22 | Pfizer Inc | 2-aminocarbonyl-9H-purine derivatives |
US6921753B2 (en) | 2000-06-27 | 2005-07-26 | Pfizer Inc | Purine derivatives |
GB0015727D0 (en) | 2000-06-27 | 2000-08-16 | Pfizer Ltd | Purine derivatives |
GB0016002D0 (en) | 2000-06-29 | 2000-08-23 | Glaxo Group Ltd | Novel process for preparing crystalline particles |
IL155093A0 (en) | 2000-09-29 | 2003-10-31 | Glaxo Group Ltd | Morpholin-acetamide derivatives for the treatment on inflammatory diseases |
AU2002210761A1 (en) | 2000-11-03 | 2002-05-15 | Glaxo Group Limited | Method of determining susceptibility to diseases |
GB0028383D0 (en) | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
GB0031179D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Nitric oxide synthase inhibitors |
DE10064997A1 (en) | 2000-12-23 | 2002-06-27 | Merck Patent Gmbh | New 1-benzoyl-3-phenyl-tetrahydropyridazine derivatives, useful for treating e.g. allergy, are selective inhibitors of phosphodiesterase IV, and new intermediates |
US6484903B2 (en) | 2001-01-09 | 2002-11-26 | Riverwood International Corporation | Carton with an improved dispensing feature in combination with a unique handle |
WO2002055085A2 (en) | 2001-01-16 | 2002-07-18 | Can-Fite Biopharma Ltd. | Use of an adenosine a3 receptor agonist for inhibition of viral replication |
ATE293109T1 (en) | 2001-01-31 | 2005-04-15 | Pfizer Prod Inc | NICOTINIC ACID AMIDE DERIVATIVES AND THEIR MIMETICS AS INHIBITORS OF PDE4 ISOZYMS |
US7250518B2 (en) | 2001-01-31 | 2007-07-31 | Pfizer Inc. | Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes |
GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
GB0104555D0 (en) | 2001-02-23 | 2001-04-11 | Glaxo Group Ltd | New Therapeutic method |
GB2372742A (en) | 2001-03-03 | 2002-09-04 | Univ Leiden | C2,5'-Disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and their different uses |
WO2002070490A1 (en) | 2001-03-08 | 2002-09-12 | Glaxo Group Limited | Agonists of beta-adrenoceptors |
WO2002072067A2 (en) | 2001-03-12 | 2002-09-19 | Glaxo Group Limited | Pharmaceutical aerosol formulation |
EP1370521B1 (en) | 2001-03-22 | 2007-12-19 | Glaxo Group Limited | Formanilide derivatives as beta2-adrenoreceptor agonists |
NZ528406A (en) | 2001-03-30 | 2004-03-26 | Pfizer Prod Inc | Pyridazinone aldose reductase inhibitors |
US20040204481A1 (en) | 2001-04-12 | 2004-10-14 | Pnina Fishman | Activation of natural killer cells by adenosine A3 receptor agonists |
US6903109B2 (en) | 2001-04-18 | 2005-06-07 | Ortho-Muniel Pharmaceutical, Inc. | Arylindenopyridines and related therapeutic and prophylactic methods |
GB0120124D0 (en) | 2001-05-04 | 2001-10-10 | Aventis Pharm Prod Inc | Effect of timing and duration of administration of amp 579 on reperfusion injury in rabbit heart |
US20030013675A1 (en) | 2001-05-25 | 2003-01-16 | Boehringer Ingelheim Pharma Kg | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases |
PA8546101A1 (en) | 2001-05-25 | 2003-12-10 | Pfizer | AN A2A ANTAGONIST IN COMBINATION WITH AN ANTI-POLINERGIC AGENT FOR THE TREATMENT OF OBSTRUCTIVE DISEASES OF THE AIRWAYS |
US7262176B2 (en) | 2001-08-08 | 2007-08-28 | Cv Therapeutics, Inc. | Adenosine A3 receptor agonists |
US20030078232A1 (en) | 2001-08-08 | 2003-04-24 | Elfatih Elzein | Adenosine receptor A3 agonists |
USRE44874E1 (en) | 2001-09-14 | 2014-04-29 | Glaxo Group Limited | Phenethanolamine derivatives for treatment of respiratory diseases |
EP1434782A2 (en) * | 2001-10-01 | 2004-07-07 | University of Virginia Patent Foundation | 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof |
MXPA04003668A (en) | 2001-10-31 | 2004-07-22 | Merck Patent Gmbh | Type 4 phosphodiesterase inhibitors and uses thereof. |
RU2004116686A (en) | 2001-11-02 | 2005-03-27 | Авентис Фармасьютикалз Инк. (Us) | PHARMACEUTICAL COMPOSITION, INCLUDING A1 / A2-Adenosine Receptor Agonist and Sodium-Hydrogen Ion Exchange Inhibitor |
MXPA04004263A (en) | 2001-11-05 | 2004-07-08 | Merck Patent Gmbh | Hydrazono-malonitriles. |
WO2003042160A1 (en) | 2001-11-13 | 2003-05-22 | Theravance, Inc. | Aryl aniline beta-2 adrenergic receptor agonists |
US6911453B2 (en) | 2001-12-05 | 2005-06-28 | Aventis Pharma Deutschland Gmbh | Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them |
GB0129273D0 (en) | 2001-12-06 | 2002-01-23 | Pfizer Ltd | Crystalline drug form |
US6703405B2 (en) | 2001-12-22 | 2004-03-09 | Aventis Pharma Deutschland Gmbh | Substituted 4-phenyltetrahydroisoquinolinium salts, process for their preparation, their use as a medicament, and medicament containing them |
DE10163991A1 (en) | 2001-12-24 | 2003-07-03 | Merck Patent Gmbh | Pyrrolo-pyrimidine |
ES2276038T3 (en) | 2002-01-14 | 2007-06-16 | Boehringer Ingelheim Pharmaceuticals Inc. | MIMETICS OF GLUCOCORTICOIDS, METHODS FOR OBTAINING THEM, PHARMACEUTICAL FORMULATIONS CONTAINING THEMSELVES AND USES OF THE SAME. |
WO2003062256A1 (en) | 2002-01-17 | 2003-07-31 | Ribapharm Inc. | 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents |
WO2003061651A1 (en) | 2002-01-22 | 2003-07-31 | The Regents Of The University Of California | Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof |
GB0201677D0 (en) | 2002-01-25 | 2002-03-13 | Glaxo Group Ltd | Medicament dispenser |
EP1469864A1 (en) | 2002-01-25 | 2004-10-27 | Muscagen Limited | Compounds useful as a-3 adenosine receptor agonists |
US6756392B2 (en) | 2002-02-11 | 2004-06-29 | Pfizer Inc | Nicotinamide derivatives useful as PDE4 inhibitors |
DE60317466T2 (en) | 2002-02-11 | 2008-03-06 | Pfizer Inc. | Nicotinamide derivatives which can be used as PDE4 inhibitors |
GB0204719D0 (en) | 2002-02-28 | 2002-04-17 | Glaxo Group Ltd | Medicinal compounds |
CA2477592A1 (en) | 2002-03-18 | 2003-09-25 | Yamanouchi Pharmaceutical Co., Ltd. | Powdery medicinal compositions for inhalation and process for producing the same |
NZ535314A (en) | 2002-03-18 | 2007-08-31 | Schering Corp | Combination treatments for chemokine-mediated diseases |
GB0206657D0 (en) | 2002-03-21 | 2002-05-01 | Glaxo Group Ltd | Novel intermediate and process |
GB0206655D0 (en) * | 2002-03-21 | 2002-05-01 | Glaxo Group Ltd | Novel process |
EP1490317A1 (en) | 2002-03-26 | 2004-12-29 | Boehringer Ingelheim Pharmaceuticals Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
EA008830B1 (en) | 2002-03-26 | 2007-08-31 | Бёрингер Ингельхайм Фармасьютиклз, Инк. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
DE10215316C1 (en) | 2002-04-02 | 2003-12-18 | Schering Ag | Quinoline and isoquinoline derivatives, a pharmaceutical agent and their use as anti-inflammatory agents |
EP1496892B1 (en) | 2002-04-11 | 2011-01-26 | Merck Sharp & Dohme Corp. | 1h-benzo(f)indazol-5-yl derivatives as selective glucocorticoid receptor modulators |
GB0208608D0 (en) | 2002-04-13 | 2002-05-22 | Glaxo Group Ltd | Composition |
US20040127510A1 (en) | 2002-04-16 | 2004-07-01 | Heintzelman Geoffrey R. | Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods |
JP2005523920A (en) | 2002-04-25 | 2005-08-11 | グラクソ グループ リミテッド | Phenetanolamine derivative |
WO2003099290A1 (en) | 2002-05-21 | 2003-12-04 | Glaxo Group Limited | Pharmaceutical products and methods of manufacture |
US7186864B2 (en) | 2002-05-29 | 2007-03-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
US7074806B2 (en) | 2002-06-06 | 2006-07-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
JP4503436B2 (en) | 2002-07-08 | 2010-07-14 | ファイザー・プロダクツ・インク | Glucocorticoid receptor modulators |
PL375442A1 (en) | 2002-07-18 | 2005-11-28 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor and method |
US7442554B2 (en) | 2002-07-18 | 2008-10-28 | Bristol-Myers Squibb Company | Compositions and methods involving glucocorticoid receptor site II |
GB0217225D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
ATE403648T1 (en) | 2002-08-21 | 2008-08-15 | Boehringer Ingelheim Pharma | SUBSTITUTED DIHYDROCINOLINES AS GLUCOCORTICOID MIMMETICS, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS AND THEIR USE |
AU2003265867A1 (en) | 2002-08-29 | 2004-10-18 | Oxford Glycosciences (Uk) Ltd. | A3 receptor-mediated cardioprotective proteins and therapeutic and diagnostic methods of use |
GB0220730D0 (en) | 2002-09-06 | 2002-10-16 | Glaxo Group Ltd | Medicinal compounds |
US7112572B2 (en) | 2002-09-09 | 2006-09-26 | Trigen Limited | Multivalent metal salts of boronic acids |
DE60330250D1 (en) | 2002-09-09 | 2010-01-07 | Cv Therapeutics Inc | ADENOSINE A3 RECEPTOR AGONISTS |
PT1396270E (en) | 2002-09-09 | 2006-08-31 | Trigen Ltd | PROCESS FOR THE PREPARATION OF UTEISNCOMO INTERMEDIATE COMPOUNDS. |
PL375993A1 (en) | 2002-09-16 | 2005-12-12 | Glaxo Group Limited | Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors |
SI2298338T1 (en) | 2002-09-16 | 2012-11-30 | Agennix Inc | Lactoferrin compositions and methods of treatment of skin wounds |
US20040229780A1 (en) | 2002-09-20 | 2004-11-18 | Olivera Baldomero M. | KappaM-conopeptides as organ protectants |
JP4520309B2 (en) | 2002-09-20 | 2010-08-04 | メルク・シャープ・エンド・ドーム・コーポレイション | Octahydro-2-H-naphtho [1,2-f] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators |
AU2003270752A1 (en) | 2002-09-27 | 2004-04-19 | King Pharmaceuticals Research And Development, Inc. | A method to demonstrate the efficacy of pharmacological stress agent |
WO2004030621A2 (en) | 2002-09-30 | 2004-04-15 | The Trustees Of Boston University | Method of treating cancer using adenosine and its analogs |
EP1551818B1 (en) | 2002-10-09 | 2009-02-04 | Schering Corporation | Thiadiazoledioxides and thiadiazoleoxides as cxc- and cc-chemokine receptor ligands |
KR20050047552A (en) | 2002-10-11 | 2005-05-20 | 화이자 인코포레이티드 | Indole derivatives as beta-2 agonists |
EP1407769A1 (en) | 2002-10-11 | 2004-04-14 | Pfizer Limited | Indole derivatives as beta-2 agonists |
US6844362B2 (en) | 2002-10-11 | 2005-01-18 | Pfizer Inc | Indole derivatives useful for the treatment of diseases |
JP2006506373A (en) | 2002-10-22 | 2006-02-23 | グラクソ グループ リミテッド | Pharmaceutical arylethanolamine compounds |
US7199127B2 (en) | 2002-10-25 | 2007-04-03 | United States Of America, Represented By The Secretary, Department Of Health And Human Services | Purine nucleosides |
GB0225030D0 (en) | 2002-10-28 | 2002-12-04 | Glaxo Group Ltd | Medicinal compounds |
WO2004037773A1 (en) | 2002-10-28 | 2004-05-06 | Glaxo Group Limited | Phenethanolamine derivative for the treatment of respiratory diseases |
GB0225540D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
GB0225535D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
EP1567161A4 (en) | 2002-12-03 | 2008-09-03 | Vela Acquisition Corp | Pharmaceutical composition of 1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5h-2,3-benzodiazepine and uses thereof |
GB0228723D0 (en) | 2002-12-09 | 2003-01-15 | Cambridge Biotechnology Ltd | Treatment of pain |
CA2451267A1 (en) | 2002-12-13 | 2004-06-13 | Warner-Lambert Company Llc | Pharmaceutical uses for alpha2delta ligands |
CA2512819A1 (en) | 2003-01-14 | 2004-07-29 | Altana Pharma Ag | Pde4 inhibitors for the treatment of neoplasms of lymphoid cells |
US20040166574A1 (en) | 2003-02-25 | 2004-08-26 | Antonius John I. | Microorganism |
US20040175382A1 (en) | 2003-03-06 | 2004-09-09 | Schafer Peter H. | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
GB0305153D0 (en) | 2003-03-07 | 2003-04-09 | Cambridge Biotechnology Ltd | Identification of therapeutic compounds |
GB0305149D0 (en) | 2003-03-07 | 2003-04-09 | Cambridge Biotechnology Ltd | Compounds for the treatment of pain |
GB0305150D0 (en) | 2003-03-07 | 2003-04-09 | Cambridge Biotechnology Ltd | Use of therapeutic compounds |
EP1460064A1 (en) | 2003-03-14 | 2004-09-22 | Pfizer Limited | Indole-2-carboxamide derivatives useful as beta-2 agonists |
US20040184995A1 (en) | 2003-03-17 | 2004-09-23 | Yamanouchi Pharmaceutical Co., Ltd. | Novel dry powder inhalation for lung-delivery and manufacturing method thereof |
US20040258740A1 (en) | 2003-04-10 | 2004-12-23 | Nene Labs | Transdermal delivery composition |
JP2006523674A (en) | 2003-04-18 | 2006-10-19 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | Combination therapy for chronic obstructive pulmonary disease (COPD) |
US7268147B2 (en) | 2003-05-15 | 2007-09-11 | Pfizer Inc | Compounds useful for the treatment of diseases |
EP1477167A1 (en) | 2003-05-15 | 2004-11-17 | Pfizer Limited | [(2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propyl] phenyl derivatives as beta2 agonists |
TWI328009B (en) | 2003-05-21 | 2010-08-01 | Glaxo Group Ltd | Quinoline derivatives as phosphodiesterase inhibitors |
GB0312832D0 (en) | 2003-06-04 | 2003-07-09 | Pfizer Ltd | 2-amino-pyridine derivatives useful for the treatment of diseases |
US7067541B2 (en) | 2003-06-04 | 2006-06-27 | Pfizer Inc | 2-amino-pyridine derivatives useful for the treatment of diseases |
US7375100B2 (en) | 2003-06-04 | 2008-05-20 | Pfizer Inc | 2-amino-pyridine derivatives useful for the treatment of diseases |
ATE384697T1 (en) | 2003-06-04 | 2008-02-15 | Pfizer | 2-AMINO-PYRIDINE DERIVATIVES AS BETA-2 ADRENORECEPTOR AGONISTS |
WO2004110454A1 (en) | 2003-06-13 | 2004-12-23 | Ishihara Sangyo Kaisha, Ltd. | COMPOSITION FOR TREATMENT FOR OR PREVENTION OF DISEASE NECESSITATING ADMINISTRATION OF ADENOSINE A2a RECEPTOR AGONIST |
US6974862B2 (en) | 2003-06-20 | 2005-12-13 | Kensey Nash Corporation | High density fibrous polymers suitable for implant |
US7132435B2 (en) | 2003-07-25 | 2006-11-07 | Pfizer Inc. | Compounds |
GB0317482D0 (en) | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as pde4 inhibitors |
US7153870B2 (en) | 2003-07-25 | 2006-12-26 | Pfizer Inc. | Nicotinamide derivatives useful as PDE4 inhibitors |
GB0317484D0 (en) | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as pde4 inhibitors |
GB0317498D0 (en) | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Compounds |
GB0317509D0 (en) | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as PDE4 inhibitors |
GB0317471D0 (en) | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Novel compounds |
GB0317516D0 (en) | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as PDE4 inhibitors |
US20050020587A1 (en) | 2003-07-25 | 2005-01-27 | Pfizer Inc | Nicotinamide derivatives useful as PDE4 inhibitors |
GB0317472D0 (en) | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as PDE4 inhibitors |
GB0317951D0 (en) | 2003-07-31 | 2003-09-03 | Trigen Ltd | Compounds |
WO2005028489A2 (en) | 2003-09-18 | 2005-03-31 | King Pharmaceuticals Research & Development, Inc. | Novel adenosine a3 receptor agonists |
PE20060272A1 (en) * | 2004-05-24 | 2006-05-22 | Glaxo Group Ltd | (2R, 3R, 4S, 5R, 2'R, 3'R, 4'S, 5'S) -2.2 '- {TRANS-1,4-CYCLOHEXANODIYLBIS- [IMINO (2 - {[2- (1-METHYL- 1H-IMIDAZOL-4-IL) ETHYL] AMINO} -9H-PURIN-6,9-DIYL)]} BIS [5- (2-ETHYL-2H-TETRAZOLE-5-IL) TETRAHYDRO-3,4-FURANODIOL] AS AN A2A AGONIST |
-
2005
- 2005-07-19 GB GBGB0514809.3A patent/GB0514809D0/en not_active Ceased
-
2006
- 2006-07-17 AR ARP060103052A patent/AR054559A1/en not_active Application Discontinuation
- 2006-07-17 TW TW095126065A patent/TW200740814A/en unknown
- 2006-07-17 WO PCT/EP2006/007078 patent/WO2007009757A1/en not_active Application Discontinuation
- 2006-07-17 JP JP2008521876A patent/JP5010599B2/en not_active Expired - Fee Related
- 2006-07-17 EP EP06791541A patent/EP1904512B1/en active Active
- 2006-07-17 PE PE2006000855A patent/PE20070179A1/en not_active Application Discontinuation
- 2006-07-17 US US11/995,921 patent/US7985740B2/en not_active Expired - Fee Related
- 2006-07-17 ES ES06791541T patent/ES2387404T3/en active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2009501746A5 (en) | ||
EP3194382B1 (en) | Pyrazole derivatives as sgc stimulators | |
JP6263533B2 (en) | Dihydropyrimidine compounds and their application in medicine | |
RU2331642C2 (en) | New kinase inhibitors | |
JP2004517855A5 (en) | ||
LU92602I2 (en) | Trametinib, optionally in the form of a pharmaceutically acceptable salt, hydrate or solvate thereof | |
JP2019507774A (en) | Elimination of hepatitis B virus by antiviral agents | |
CN105008350B (en) | Antiviral compound | |
JP2016515545A (en) | HCV RNA-polymerase NS5B nucleoside inhibitor, 2-{[(2R, 3S, 5R) -5- (4-amino-2-oxo-2H-pyrimidin-1-yl) -3-hydroxy-tetrahydro-furan -2-ylmethoxy] -phenoxy-phosphorylamino} -alkyl propionate, process for its preparation and use | |
JP2006504658A5 (en) | ||
JP2008543781A5 (en) | ||
RU2008145704A (en) | PURINE DERIVATIVES AS A2A RECEPTOR AGONISTS | |
RU2007101236A (en) | NEW HYDANTOINE DERIVATIVES FOR TREATMENT OF OBSTRUCTIVE RESPIRATORY DISEASES | |
PE20110063A1 (en) | DERIVATIVES OF [1, 2, 4] TRIAZOLO [1, 5-a] PYRIDINE AS JAK INHIBITORS | |
PE20070179A1 (en) | PURINE DERIVATIVES AS AGONISTS OF THE ADENOSINE A2 RECEPTOR | |
JP2006077019A5 (en) | ||
JP2008523041A5 (en) | ||
JP2010529147A5 (en) | ||
NO20084853L (en) | Compounds that are agonists of muscarinic receptors and which may be effective in the treatment of pain, Alzheimer's disease and / or schizophrenia | |
PE20060602A1 (en) | HETEROARYL ACIL PYRROLIDINE DERIVATIVES AS INHIBITORS OF HEPATITIS C VIRUS (HCV) | |
JP2009525340A5 (en) | ||
JP2013531074A5 (en) | ||
RU2013104038A (en) | SELECTIVE WITH RESPECT TO PI3K p110 DELTA PURINE COMPOUNDS AND WAYS OF THEIR APPLICATION | |
RU2012139828A (en) | Pyrazolopyiperidine derivatives as Nadph Oxidase Inhibitors | |
RU2354655C2 (en) | Comt inhibitors |